Piper Says Myriad Appears To Be Trading Down On GeneSight Coverage Change

1, 2024, 04:55 am. Analyst brandon couillard from wells. Two crossed lines that form an 'x'. It indicates a way to close an interaction, or dismiss a notification. Myriad genetics stock broke out of a cup base at 35. 34 on aug.

On wednesday, it gave back all those gains. Based on the risk to genesight and reimbursement pressures, piper jaffray downgraded myriad from a maintain overweight rating to neutral and lowered its stock pricing. Piper sandler initiated coverage on myriad genetics inc (nasdaq: Mygn), noting that many investors know the company as one of the earliest pioneers of genetic. Myriad genetics (nasdaq:mygn) is down ~20%in friday trading following reports that unitedhealth group (unh) will no longer cover the company's genetic test that helps to. Leerink keeps an outperform rating on myriad genetics after the company disclosed that it is discontinuing phase 2 of an economic impact study on genesight because.